Metformin

Caroline Day*, Clifford J. Bailey

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

Abstract

Metformin is the only biguanide antihyperglycemic agent used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. It counters insulin resistance partly by increased insulin action (so-called insulin sensitizing effects) and partly via actions that are not directly insulin dependent. Metformin reduces hepatic glucose output by suppression of gluconeogenesis and glycogenolysis. In skeletal muscle, metformin increases insulin-mediated glucose uptake and glycogen storage. Other actions of metformin that contribute to its blood glucose-lowering effect are reduced fatty acid oxidation and increased glucose turnover, the latter occurring particularly in the splanchnic bed .... © 2007

Original languageEnglish
Title of host publicationxPharm
Subtitle of host publicationthe comprehensive pharmacology reference
EditorsS.J. Enna, David B. Bylund
PublisherElsevier
Number of pages4
ISBN (Print)978-0-08-055232-3
DOIs
Publication statusPublished - 1 Dec 2011

Fingerprint Dive into the research topics of 'Metformin'. Together they form a unique fingerprint.

  • Biguanides

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 3 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

  • Ciglitazone

    Day, C. & Bailey, C. J., Feb 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 2 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

  • Pioglitazone

    Day, C. & Bailey, C. J., 1 Dec 2011, xPharm: the comprehensive pharmacology reference. Enna, S. J. & Bylund, D. B. (eds.). Elsevier, 4 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)peer-review

Cite this